Alps Advisors Inc. Sells 45,991 Shares of LianBio (NASDAQ:LIAN)

Alps Advisors Inc. trimmed its holdings in LianBio (NASDAQ:LIANGet Rating) by 41.7% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 64,228 shares of the company’s stock after selling 45,991 shares during the period. Alps Advisors Inc.’s holdings in LianBio were worth $139,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Bailard Inc. lifted its position in shares of LianBio by 29.0% in the second quarter. Bailard Inc. now owns 47,597 shares of the company’s stock valued at $103,000 after buying an additional 10,697 shares during the last quarter. Citigroup Inc. acquired a new stake in shares of LianBio in the first quarter valued at approximately $1,980,000. Alyeska Investment Group L.P. lifted its position in shares of LianBio by 19.1% in the first quarter. Alyeska Investment Group L.P. now owns 339,242 shares of the company’s stock valued at $1,259,000 after buying an additional 54,392 shares during the last quarter. Affinity Asset Advisors LLC lifted its position in shares of LianBio by 348.9% in the first quarter. Affinity Asset Advisors LLC now owns 325,000 shares of the company’s stock valued at $1,206,000 after buying an additional 252,594 shares during the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of LianBio in the first quarter valued at approximately $160,000. 79.94% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Raymond James cut their price objective on LianBio from $27.00 to $15.00 and set an “outperform” rating for the company in a research report on Friday, October 14th.

LianBio Trading Up 1.9 %

NASDAQ:LIAN opened at $1.60 on Thursday. The stock has a market cap of $173.37 million and a P/E ratio of -1.42. The stock has a 50 day simple moving average of $1.71 and a 200 day simple moving average of $2.23. LianBio has a 1-year low of $1.07 and a 1-year high of $16.11.

LianBio Profile

(Get Rating)

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.

Read More

Want to see what other hedge funds are holding LIAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LianBio (NASDAQ:LIANGet Rating).

Institutional Ownership by Quarter for LianBio (NASDAQ:LIAN)

Receive News & Ratings for LianBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LianBio and related companies with MarketBeat.com's FREE daily email newsletter.